John J. Piwinski
Ohio Aerospace Institute(US)
Publications by Year
Research Areas
Receptor Mechanisms and Signaling, Mast cells and histamine, Neuropeptides and Animal Physiology, Chemical Synthesis and Analysis, Hepatitis C virus research
Most-Cited Works
- → Discovery of (1 R ,5 S )- N -[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2( S )-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2( S )-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection(2006)278 cited
- → Challenges in Modern Drug Discovery: A Case Study of Boceprevir, an HCV Protease Inhibitor for the Treatment of Hepatitis C Virus Infection(2008)261 cited
- → Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor(2010)97 cited
- → Tricyclic Farnesyl Protein Transferase Inhibitors: Crystallographic and Calorimetric Studies of Structure−Activity Relationships(1999)88 cited
- → Asymmetric Synthesis of 4,4-Disubstituted-2-Imidazoli-dinones: Potent NK1 Antagonists(2003)70 cited
- → Discovery and SAR of hydantoin TACE inhibitors(2010)57 cited
- → Dual antagonists of platelet-activating factor and histamine. Identification of structural requirements for dual activity of N-acyl-4-(5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidines(1991)56 cited
- → Discovery and Structure−Activity Relationship of P1−P3 Ketoamide Derived Macrocyclic Inhibitors of Hepatitis C Virus NS3 Protease(2008)52 cited
- → Discovery of novel nonpeptide tricyclic inhibitors of ras farnesyl protein transferase(1997)48 cited
- → Cyclic urea derivatives as potent NK1 selective antagonists(2005)47 cited